Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques

• Ngā kaituhi matua: G. J. Gatto (Author), A. Krovi (Author), L. Li (Author), I. Massud (Author), A. Holder (Author), J. Gary (Author), P. Mills (Author), J. Mitchell (Author), E. Luecke (Author), Z. R. Demkovich (Author), W. Heneine (Author), J. G. García-Lerma (Author), M. A. Marzinke (Author), R. M. Brand (Author), C. W. Dobard (Author), L. M. Johnson (Author), A. Van Der Straten (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

The administration of antiretrovirals (ARVs) for HIV pre-exposure prophylaxis (PrEP) is highly efficacious and may benefit from new long-acting (LA) drug delivery approaches. This paper describes a subcutaneous, reservoir-style implant for the LA delivery of tenofovir alafenamide (TAF) and documents...